Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epoetin beta therapy in patients with solid tumours.

Paolo Pronzato1, Jacek Jassem, Jose Mayordomo

  • 1Medical Oncology, S. Andrea Hospital, La Spezia, Italy. ppronza@tin.it

Critical Reviews in Oncology/Hematology
|September 20, 2005
PubMed
Summary

Epoetin beta effectively treats cancer-related anaemia, improving quality of life and reducing transfusions. This therapy is safe and convenient for cancer patients, with no negative impact on survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Nature cancer·2026
Same author

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.

Current oncology reports·2026
Same author

Mutational landscapes of brain metastases across various histological subtypes of lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center.

BMC cancer·2026
Same author

Prospects for implementing the European Code of Cancer Practice: Lessons from Poland.

Health policy (Amsterdam, Netherlands)·2026

Area of Science:

  • Oncology
  • Hematology

Background:

  • Cancer and its treatments frequently cause anemia, impacting patient quality of life and treatment outcomes.
  • Anemia in cancer patients is linked to fatigue, reduced physical function, and poorer survival rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of epoetin beta in managing cancer-related anemia.
  • To assess the impact of epoetin beta on hemoglobin levels, transfusion needs, quality of life, and survival in cancer patients.

Main Methods:

  • Review of various studies and a meta-analysis involving epoetin beta treatment in cancer patients with solid tumors and malignancies.
  • Assessment of outcomes including hemoglobin levels, blood transfusion requirements, quality of life indicators, tumor progression, and survival.

Related Experiment Videos

Main Results:

  • Epoetin beta effectively increases hemoglobin levels and reduces the need for blood transfusions across different chemotherapy regimens.
  • Significant improvements in quality of life, including reduced fatigue and enhanced daily activity, were observed.
  • Meta-analysis indicated no adverse effect on survival or thrombosis-related survival, with a potential reduction in tumor progression risk.

Conclusions:

  • Epoetin beta is an effective, safe, and convenient therapeutic option for managing anemia in patients with cancer.
  • The treatment improves patient-reported outcomes and may offer survival benefits or reduce tumor progression.
  • Once-weekly administration of epoetin beta is as effective as thrice-weekly dosing.